National Alliance on Mental Illness
page printed from http://www.nami.org/
(800) 950-NAMI; email@example.com
FDA Investigates Two Deaths Following Injection of Long-Acting Antipsychotic Zyprexa Relprevv
The U.S. Food and Drug Administration (FDA) has announced that it is investigating two unexplained deaths in patients who received an intramuscular injection of a new compound, the antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). Zyprexa Relprevv is a long-acting antipsychotic used in the treatment of schizophrenia. NAMI is monitoring information as it becomes available. Patients and caregivers should talk to their doctors with any questions or concerns. See the FDA Notice for more information.